Nicolas Bizat
Centre national de la recherche scientifique
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Nicolas Bizat.
Journal of Cerebral Blood Flow and Metabolism | 2000
Caroline Dautry; Françoise Vaufrey; Emmanuel Brouillet; Nicolas Bizat; Pierre Gilles Henry; Françoise Condé; Gilles Bloch; Philippe Hantraye
N-acetylaspartate (NAA) quantification by 1H-magnetic resonance spectroscopy has been commonly used to assess in vivo neuronal loss in neurodegenerative disorders. Here, the authors used ex vivo and in vivo1H-magnetic resonance spectroscopy in rat and primate models of progressive striatal degeneration induced by the mitochondrial toxin 3-nitropropionate (3NP) to determine whether early NAA depletions could also be associated with neuronal dysfunction. In rats that were treated for 3 days with 3NP and had motor symptoms, the authors found a significant decrease in NAA concentrations, specifically restricted to the striatum. No cell loss or dying cells were found at this stage in these animals. After 5 days of 3NP treatment, a further decrease in striatal NAA concentrations was observed in association with the occurrence of dying neurons in the dorsolateral striatum. In 3NP-treated primates, a similar striatal-selective and early decrease in NAA concentrations was observed after only a few weeks of neurotoxic treatment, without any sign of ongoing cell death. This early decrease in striatal NAA was partially reversed after 4 weeks of 3NP withdrawal. These results demonstrate that early NAA depletions reflect a reversible state of neuronal dysfunction preceding cell degeneration and suggest that in vivo quantification of NAA 1H-magnetic resonance spectroscopy may become a valuable tool for assessing early neuronal dysfunction and the effects of potential neuroprotective therapies in neurodegenerative disorders.
Neurobiology of Disease | 2004
Lichuan Yang; Shuei Sugama; Ronald P. Mischak; Mahmoud Kiaei; Nicolas Bizat; Emmanuel Brouillet; Tong H. Joh; M. Flint Beal
Molecular machinery involved in apoptosis plays a role in neuronal death in neurodegenerative disorders such as Parkinsons disease (PD) and Huntingtons disease (HD). Several caspase inhibitors, such as the well-known peptidyl inhibitor carbobenzoxy-Val-Ala-Asp-fluoromethylketone (zVADfmk), can protect neurons from apoptotic death caused by mitochondrial toxins. However, the poor penetrability of zVADfmk into brain and toxicity limits its use therapeutically. In the present study, a novel peptidyl broad-spectrum caspase inhibitor, Q-VD-OPH, which offers improvements in potency, stability, and toxicity over zVADfmk, showed significant protection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 3-nitropropionic acid (3NP), and malonate toxicities. Q-VD-OPH significantly reduced dopamine depletion in striatum produced by MPTP administration and prevented MPTP-induced loss of dopaminergic neurons in the substantia nigra. It significantly reduced the size of striatal lesions produced by intrastriatal malonate injections and systemic administration of 3NP. Western blots performed on tissues from the midbrain following administration of MPTP or the striatum in 3NP-treated animals showed increases of the active forms of caspase-9 and caspase-8, as well as the caspase-8-mediated proapoptotic protein Bid, which were inhibited Q-VD-OPH treatment. These findings suggest that systematically active broad-spectrum caspase inhibitors maybe useful in the treatment of neurodegenerative diseases such as PD and HD.
Neurobiology of Disease | 2004
Marie-Christine Galas; Nicolas Bizat; Laetitia Cuvelier; Kadiombo Bantubungi; Emmanuel Brouillet; Serge N. Schiffmann; David Blum
An important aspect of Huntingtons disease (HD) pathogenesis which may have important therapeutic implications is that the cellular events leading to cell death may be different in cortical and striatal neurons. In the present study, we characterized cellular changes in cortical and striatal neurons treated with the mitochondrial toxin 3-nitropropionic acid (3NP) in culture. Degeneration induced by 3NP was similar in both striatal and cortical neurons as observed using markers of cell viability and DNA fragmentation. However, in striatal neurons, 3NP produced a marked delocalization of Bad, Bax, cytochrome c and Smac while this was not observed in cortical neurons. Death of striatal neurons was preceded by activation of calpain and was blocked by calpain inhibitor I. In cortical neurons, calpain was not activated and calpain inhibitor I was without effect. In both cell types, caspase-9 and -3 were not activated by 3NP and the caspase inhibitor zVAD-fmk did not provide neuroprotective effect. Interestingly, treatment with staurosporine (STS) triggered caspase-9 and -3 in cortical and striatal cells, suggesting that the molecular machinery related to caspase-dependent apoptosis was functional in both cell types even though this machinery was not involved in 3NP toxicity. The present results clearly demonstrate that under mitochondrial inhibition, striatal and cortical neurons die through different pathways. This suggests that mitochondrial defects in HD may trigger the death of cortical and striatal neurons through different molecular events.
Neuroreport | 2004
Isabel Lastres-Becker; Nicolas Bizat; Frédéric Boyer; Philippe Hantraye; Javier Fernández-Ruiz; Emmanuel Brouillet
Several neurotransmitter systems are involved in the pathogenesis of Huntingtons disease. Here, we examined the involvement of cannabinoid CB1 receptors in striatal degeneration in the rat model of this disease generated by administration of 3-nitropropionic acid (3NP). Several days before onset of striatal degeneration, G-protein activation by cannabinoid agonists was significantly decreased whereas density and mRNA levels of CB1 receptors remained essentially normal. This change was transient, CB1 receptors recovering full functionality after few days. Later, at onset of striatal degeneration, profound alterations of CB1 receptors were detected, including marked reductions of their density, mRNA levels and coupling to G proteins. In these rats, the administration of the cannabinoid agonist Δ9-tetrahydrocannabinol was neuroprotective, which indicates that the early loss of CB1 receptor signaling could be instrumental in 3NP toxicity. In conclusion, the present study supports the hypothesis that cannabinoid receptors, possibly the CB1 receptor subtype, may be involved in HD pathogenesis and could be an interesting therapeutic target to slow disease progression.
The Journal of Neuroscience | 2010
Nicolas Bizat; Jean-Michel Peyrin; Stéphane Haïk; Véronique Cochois; Patrick Beaudry; Jean-Louis Laplanche; Christian Neri
Although prion propagation is well understood, the signaling pathways activated by neurotoxic forms of prion protein (PrP) and those able to mitigate pathological phenotypes remain largely unknown. Here, we identify src-2, a Fyn-related kinase, as a gene required for human PrP with an insertional mutation to be neurotoxic in Caenorhabditis elegans, and the longevity modulator sir-2.1/SIRT1, a sirtuin deacetylase, as a modifier of prion neurotoxicity. The expression of octarepeat-expanded PrP in C. elegans mechanosensory neurons led to a progressive loss of response to touch without causing cell death, whereas wild-type PrP expression did not alter behavior. Transgenic PrP molecules showed expression at the plasma membrane, with protein clusters, partial resistance to proteinase K (PK), and protein insolubility detected for mutant PrP. Loss of function (LOF) of src-2 greatly reduced mutant PrP neurotoxicity without reducing PK-resistant PrP levels. Increased sir-2.1 dosage reversed mutant PrP neurotoxicity, whereas sir-2.1 LOF showed aggravation, and these effects did not alter PK-resistant PrP. Resveratrol, a polyphenol known to act through sirtuins for neuroprotection, reversed mutant PrP neurotoxicity in a sir-2.1-dependent manner. Additionally, resveratrol reversed cell death caused by mutant PrP in cerebellar granule neurons from prnp-null mice. These results suggest that Fyn mediates mutant PrP neurotoxicity in addition to its role in cellular PrP signaling and reveal that sirtuin activation mitigates these neurotoxic effects. Sirtuin activators may thus have therapeutic potential to protect from prion neurotoxicity and its effects on intracellular signaling.
Neuropharmacology | 2005
Nicolas Bizat; Marie-Christine Galas; Carine Jacquard; Frédéric Boyer; Jean-Michel Hermel; Serge N. Schiffmann; Philippe Hantraye; David Blum; Emmanuel Brouillet
The contribution of calpains and caspases to cell death has been widely studied using pharmacological inhibitors. Among them, the caspase inhibitor N-benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethylketone (zVAD) has been used as a specific caspase inhibitor in nearly 1000 published studies. However, several studies showed that zVAD also behaves as a calpain inhibitor in peripheral cells. The effects of zVAD as a calpain inhibitor have never been assessed in neurodegeneration models. We examined here whether zVAD could reduce neurodegeneration in Huntingtons disease models using the mitochondrial inhibitor 3-nitropropionic acid (3NP). In these models, 3NP toxicity has been shown to require calpain activation. In rats, intra-cerebro-ventricular infusion of zVAD significantly reduced 3NP-induced striatal degeneration, and decreased the 3NP-induced activation of calpain and calpain-dependent cleavage of fodrin. zVAD (100 microM) also blocked 3NP-induced death of cultured striatal neurons. In vitro, zVAD inhibited purified mu-calpain with high affinity (IC50=10 nM). The present data demonstrate that zVAD protects neurons against 3NP through calpain inhibition. This suggests that, in certain models of neuronal death where zVAD showed protective effects, caspases but also calpains may be involved.
PLOS ONE | 2009
Elsa Diguet; Fanny Petit; Carole Escartin; Karine Cambon; Nicolas Bizat; Noelle Dufour; Philippe Hantraye; Nicole Déglon; Emmanuel Brouillet
Aging likely plays a role in neurodegenerative disorders. In Huntingtons disease (HD), a disorder caused by an abnormal expansion of a polyglutamine tract in the protein huntingtin (Htt), the role of aging is unclear. For a given tract length, the probability of disease onset increases with age. There are mainly two hypotheses that could explain adult onset in HD: Either mutant Htt progressively produces cumulative defects over time or “normal” aging renders neurons more vulnerable to mutant Htt toxicity. In the present study, we directly explored whether aging affected the toxicity of mutant Htt in vivo. We studied the impact of aging on the effects produced by overexpression of an N-terminal fragment of mutant Htt, of wild-type Htt or of a β-Galactosidase (β-Gal) reporter gene in the rat striatum. Stereotaxic injections of lentiviral vectors were performed simultaneously in young (3 week) and old (15 month) rats. Histological evaluation at different time points after infection demonstrated that the expression of mutant Htt led to pathological changes that were more severe in old rats, including an increase in the number of small Htt-containing aggregates in the neuropil, a greater loss of DARPP-32 immunoreactivity and striatal neurons as assessed by unbiased stereological counts. The present results support the hypothesis that “normal” aging is involved in HD pathogenesis, and suggest that age-related cellular defects might constitute potential therapeutic targets for HD.
The Journal of Infectious Diseases | 2014
Samia Hannaoui; Alexianne Gougerot; Nicolas Privat; Etienne Levavasseur; Nicolas Bizat; Jean-Jacques Hauw; Jean-Philippe Brandel; Stéphane Haïk
In prion diseases, a major issue in therapeutic research is the variability of the effect between strains. Stimulated by the report of an antiprion effect in a scrapie model and by ongoing international clinical trials using doxycycline, we studied the efficacy of cyclines against the propagation of human prions. First, we successfully propagated various Creutzfeldt-Jakob disease (CJD) isolates (sporadic, variant, and iatrogenic CJD) in neuronal cultures expressing the human prion protein. Then, we found that doxycycline was the most effective compound, with important variations between isolates. Isolates from sporadic CJD, the most common form of prion disease, showed the highest sensitivity.
Journal of Insect Physiology | 1997
Madeleine Paillette; Nicolas Bizat; Dominique Joly
Intra-specific differentiation has been investigated between two geographically isolated populations of D. teissieri, one from Brazzaville (Congo) and the other from Silinda (Zimbabwe). Courtship songs were analyzed on 23 parameters. In addition, certain parameters related to sexual activity (five) and wing morphology (five) were also examined. As in other Drosophilidae, there are two types of courtship songs resulting from wing vibration: the love song, and the sine song. Love songs from Brazzaville are longer than those from Silinda (334ms vs. 216) with a tendency to smaller and more regular inter-pulse intervals (24.56ms vs. 25.5). The sine songs (SS) are about six times longer than the love songs in each population, with an adaptation of their duration according to the receptivity of the female in Brazzaville. All the LS temporal parameters, except the interpulse interval mean, are significantly different between the two populations. The Brazzaville flies show a greater acoustic activity and have higher mating success than the Silinda ones (53.3% vs. 27.7%). Their wings are slightly shorter and wider than those from Silinda. The role of acoustic parameters, sexual activity and wing physical constraints are discussed in the perspective of incipient speciation.
The Journal of Neuroscience | 2003
Nicolas Bizat; Jean-Michel Hermel; Frédéric Boyer; Carine Jacquard; Christophe Créminon; Stéphane Ouary; Carole Escartin; Philippe Hantraye; Stan Krajewski; Emmanuel Brouillet